U.S. stock futures traded mostly lower this morning on Monday, with the Nasdaq futures falling around 50 points this morning.
Shares of Verve Therapeutics, Inc. (NASDAQ: VERV) fell in pre-market trading after the company announced first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101.
Verve Therapeutics recently reported a narrower-than-expected loss for its third quarter.
Verve Therapeutics shares fell 14.1% to $13.50 in pre-market trading
Here are some other big stocks recording losses in today’s pre-market trading session.
- Plug Power Inc. (NASDAQ: ...